Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery

This study has been completed.
Sponsor:
Collaborators:
Tampere University Hospital
Vaasa Central Hospital, Vaasa, Finland
Information provided by (Responsible Party):
Jari Halonen, Kuopio University Hospital
ClinicalTrials.gov Identifier:
NCT00784316
First received: October 31, 2008
Last updated: November 23, 2011
Last verified: November 2011
  Purpose

The aim of the study is to test the efficiency of intravenous administration of metoprolol versus intravenous administration of amiodarone in the prevention of atrial fibrillation after cardiac surgery.


Condition Intervention Phase
Atrial Fibrillation
Cardiac Surgery
Drug: metoprolol, amiodarone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery

Resource links provided by NLM:


Further study details as provided by Kuopio University Hospital:

Primary Outcome Measures:
  • Incidence of atrial fibrillation [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]

Enrollment: 316
Study Start Date: August 2007
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: metoprolol Drug: metoprolol, amiodarone
to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
Active Comparator: amiodarone Drug: metoprolol, amiodarone
to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elective CABG and aortic valve patients in cardiac surgery,
  • previous use of betablocker therapy

Exclusion Criteria:

  • previous atrial fibrillation or flutter,
  • thyroid disease,
  • uncontrolled heart failure,
  • II or III degree atrioventricular block
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00784316

Locations
Finland
Halonen jari
Kuopio, Finland, FIN- 70211
Sponsors and Collaborators
Kuopio University Hospital
Tampere University Hospital
Vaasa Central Hospital, Vaasa, Finland
  More Information

No publications provided by Kuopio University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jari Halonen, MD,PhD, Kuopio University Hospital
ClinicalTrials.gov Identifier: NCT00784316     History of Changes
Other Study ID Numbers: KUH5204005
Study First Received: October 31, 2008
Last Updated: November 23, 2011
Health Authority: Finland: Research Ethics Committee, Hospital District of Northern Savo

Keywords provided by Kuopio University Hospital:
Prevention

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Amiodarone
Metoprolol
Metoprolol succinate
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sympatholytics
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on November 27, 2014